Study of 138 #AOSD (Stills) pts - 19% were obese BMI>30. Obese with AOSD have same clinical features as others, but may have higher ferritin & CRP (correl w/ BMI) and more likely to have chronic disease course and bDMARD failure. https://t.co/16wKVGTWnN https://t.co/daR9hZpA89

Pyoderma gangrenosum review in BMJ - an ulcerative neutrophilic autoinflammatory disorder; often associated with underlying systemic disease - IBD, seronegative RA, hematological malignancies or monoclonal gammopathies, etc. https://t.co/AGorrWNfAQ https://t.co/hawksCEHRA

Prospective cohort study of 41 Stills Dz pts w/ ILD - 85% had 1+MAS & 41% with adverse reactions to a biologic. 93% were alive w/ median F/U 3 years, but 37% progressed to chronic lung dz (O2, or vent) & 84% were HLA-DRB1*15 https://t.co/fo44fgKh8m https://t.co/xa9g4Slr1H

Japanese study of 98 pts w/ VEXAS syndrome [81M: 8F; age 69.3 yrs) found 45% (40pts) with pathogenic UBA1 variants. VEXAS Dx Score based on: age >50 yrs, skin lesions, lung Sxs, chondritis, macrocytic anaemia (AUC=0.908) https://t.co/W2bSmuGf6l https://t.co/EwHuRk4GCr

Cytokine comparison of Kikuchi-Fujimoto disease (KFD) & Stills dz (pts w/ FUO and LN) shows, after excluding HLH/MAS pts, KFD pts had higher serum IFN-γ (> 8.56 pg/mL) & IFN-γ/IL-6 ratio > 0.45. Stills pts had higher serum IL-6 levels than KFD https://t.co/KYPa9OQaa5 https://t.co/70S0M9nGhp

10% of a Single center cohort (n 38) Systemic JIA pts developed MAS. Only1 had recurrent MAS(3 times), mostly Male (3M:1F) w/ mean Dx age=8 ± 6 yrs. Stills w/ MAS had less arthritis (51 v 91%), more Rash (75 v 55%), HSM (50 v 5%), serositis (25 v 5%) https://t.co/QgdSJW03wj https://t.co/L5MTnmgWDn

Patient Perspectives on Telemedicine Use During the Pandemic Research from the COVID-19 Global Rheumatology Alliance included surveys and data gathering from rheumatology patients. https://t.co/EJ5TkiDMcJ https://t.co/xBx7OIxf9h

Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/vGt12ul6iy https://t.co/044BScmSYc

Post hoc analysis 2 phase III RCTs of abatacept (Sc & IV) in 409 polyarticular JIA pcJIA. ABA was effective (by JIA-ACR and JADAS27 responses) & well tolerated, regardless of concomitant or prior MTX use. https://t.co/cTn52V5Fuu https://t.co/CUqin00LZh

Multicenter open label trial of 30 refract. Behcets (BD) pts treated w/ tocilizumab (TCZ) x 6 mos; TCZ was effective in 83% (18 complete & 7 partial resp). Complete responses seen w/ uveitis 67%, CNS 60%, mucosal 42%, articular 21%; plus steroid sparing https://t.co/PfrAoQxC2F https://t.co/ocAFv0Y2kr

In Memoriam: Dr. K. Frank Austen (1928-2023) Rheumatology mourns the loss of a historic leader in the field, Dr. K. Frank Austen, who died at his home in Maine on June 23, 2023, at the age of 95. https://t.co/mtRQ8D5bWt https://t.co/fAQ9ebK95R

RT @bella_mehta : An interesting biomarker in #sJIA- helps differentiate it from other diseases, including infections and other inflammatory diseases! - kids with fever! serum calprotectin (MRP8/14) particle enhanced immuno-turbidimeteic assay (sCAL Turbi). 650 pts #EULAR2023

RT @bella_mehta : Obesity in #AOSD – predicted the development of a chronic disease course and biologic DMARD failure, 139 pts with AOSD- 19% Obese (BMI>30) observational study. abst#AB1503 #EULAR2023

Why Patients Don't Take Medicines This report examines the characteristics of adults aged 18–64 who took prescription medication in the past 12 months and did not take medication as prescribed due to cost. https://t.co/zuPgMjKYbh https://t.co/62cG9LDYWi

Rheums! Have a rheumatology question or case for Jack Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/3atPdJwb1m https://t.co/MKbgzEi9pd

Still's Disease Abstracts at EULAR 2023 https://t.co/1gNf8RUDLi https://t.co/1f1ERUOS03